Login Register Cart 0
Generic placeholder image

Anti-Infective Agents

Editor-in-Chief

ISSN (Print): 2211-3525
ISSN (Online): 2211-3533

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in Helicobacter Pylori Eradication

Author(s): Mohammed H. Ahmed, Sherief Abd-Elsalam* and Aya M. Mahrous

Volume 19, Issue 3, 2021

Published on: 25 September, 2020

Page: [299 - 302] Pages: 4

DOI: 10.2174/2211352518999200925154501

Price: $65

Abstract

Introduction: Helicobacter pylori eradication remains a problematic issue. We are in an urgent need for finding a treatment regimen that achieves eradication at a low cost and with less side effect. Recent published results have shown a high rate of resistance with clarithromycinbased treatment regimens. The aim of the study was to compare moxifloxacin therapy and classic clarithromycin triple therapy in H. pylori eradication.

Methods: This was a pilot study that enrolled 60 patients with helicobacter pylori associated gastritis. Diagnosis was done by assessment of H. pylori Ag in the stool. The patients were randomly assigned to receive either moxifloxacin based therapy (Group A), or clarithromycin based therapy (Group B) for two weeks. We stopped the treatment for another two weeks and then re-evaluation for cure was done.

Results: 90% of patients had negative H. pylori Ag in the stool after 2 weeks of stoppage of the treatment in group A versus 66.7% in Group B. None of the patients in both the groups had major side effects.

Conclusion: Moxifloxacin-based therapy showed higher eradication power and less resistance when compared to clarithromycin triple therapy.

Keywords: Helicobacter pylori, moxifloxacin, clarithromycin, Proton Pump Inhibitors (PPI), eradication, metronidazole.

[1]
Marshall, B.J.; Warren, J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 1984, 1(8390), 1311-1315.
[http://dx.doi.org/10.1016/S0140-6736(84)91816-6] [PMID: 6145023]
[2]
Mohamed, S.M.; El Touny, M.A.E.A.; Ahmed, O.A. Prevalence of Helicobacter pylori among health care workers in endoscopy units. J. Am. Sci., 2013, 9, 192-197.
[3]
Pittman, M.E.; Khararjian, A.; Wood, L.D.; Montgomery, E.A.; Voltaggio, L. Prospective identification of Helicobacter pylori in routine gastric biopsies without reflex ancillary stains is cost-efficient for our health care system. Hum. Pathol., 2016, 58, 90-96.
[http://dx.doi.org/10.1016/j.humpath.2016.07.031] [PMID: 27574809]
[4]
Thung, I.; Aramin, H.; Vavinskaya, V.; Gupta, S.; Park, J.Y.; Crowe, S.E.; Valasek, M.A. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment. Pharmacol. Ther., 2016, 43(4), 514-533.
[http://dx.doi.org/10.1111/apt.13497] [PMID: 26694080]
[5]
Ashton-Key, M.; Diss, T.C.; Isaacson, P.G. Detection of Helicobacter pylori in gastric biopsy and resection specimens. J. Clin. Pathol., 1996, 49(2), 107-111.
[http://dx.doi.org/10.1136/jcp.49.2.107] [PMID: 8655673]
[6]
Chey, W.D.; Wong, B.C. Practice parameters committee of the american college of gastroenterology: american college of gastroenterology guideline on the management of Helicobacter pylori infection. Am. J. Gastroenterol., 2017, 2007(102), 1808-1825.
[7]
Wu, J.Y.; Liou, J.M.; Graham, D.Y. Evidence-based recommendations for successful Helicobacter pylori treatment. Expert Rev. Gastroenterol. Hepatol., 2014, 8(1), 21-28.
[http://dx.doi.org/10.1586/17474124.2014.859522] [PMID: 24410470]
[8]
Shiota, S.; Yamaoka, Y. Strategy for the treatment of Helicobacter pylori infection. Curr. Pharm. Des., 2014, 20(28), 4489-4500.
[http://dx.doi.org/10.2174/13816128113196660731] [PMID: 24180402]
[9]
Keating, G.M.; Scott, L.J. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs, 2004, 64(20), 2347-2377.
[http://dx.doi.org/10.2165/00003495-200464200-00006] [PMID: 15456331]
[10]
Abo-Amer, YE; Sabal, A; Ahmed, R Relationship between Helicobacter pylori infection and Nonalcoholic Fatty Liver Disease (NAFLD) in a Developing Country: A Cross-Sectional Study. 2020.
[11]
Nista, EC; Candelli, M; Zocco, MA Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection Aliment Pharmacol Ther, 2005, 21, 1241-1247.
[http://dx.doi.org/10.1111/j.1365-2036.2005.02412.x]
[12]
Bago, P.; Vcev, A.; Tomic, M.; Rozankovic, M.; Marusić, M.; Bago, J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien. Klin. Wochenschr., 2007, 119(11-12), 372-378.
[http://dx.doi.org/10.1007/s00508-007-0807-2] [PMID: 17634896]
[13]
Cheon, J.H.; Kim, N.; Lee, D.H.; Kim, J.M.; Kim, J.S.; Jung, H.C.; Song, I.S. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter, 2006, 11(1), 46-51.
[http://dx.doi.org/10.1111/j.0083-8703.2006.00371.x] [PMID: 16423089]
[14]
Bago, J.; Pevec, B.; Tomić, M.; Marusić, M.; Bakula, V.; Bago, P. Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien. Klin. Wochenschr., 2009, 121(1-2), 47-52.
[http://dx.doi.org/10.1007/s00508-008-1122-2] [PMID: 19263014]
[15]
Wenzhen, Y.; Kehu, Y.; Bin, M.; Yumin, L.; Quanlin, G.; Donghai, W.; Lijuan, Y. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. Intern. Med., 2009, 48(24), 2069-2076.
[http://dx.doi.org/10.2169/internalmedicine.48.2344] [PMID: 20009394]
[16]
Wu, C.; Chen, X.; Liu, J.; Li, M.Y.; Zhang, Z.Q.; Wang, Z.Q. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter, 2011, 16(2), 131-138.
[http://dx.doi.org/10.1111/j.1523-5378.2011.00826.x] [PMID: 21435091]
[17]
Alboraie, M.; Elhossary, W.; Aly, O.A.; Abbas, B.; Abdelsalam, L.; Ghaith, D.; Shady, Z.; Gaber, Y.; Adel, E.; Peura, D.; Armstrong, D.; Esmat, G. special interest group; Egyptian Association for Study of Gastrointestinal Diseases and Liver (E A S G L D). Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab J. Gastroenterol., 2019, 20(3), 175-179.
[http://dx.doi.org/10.1016/j.ajg.2019.09.001] [PMID: 31564518]
[18]
Mansour, L.; El-Kalla, F.; Kobtan, A.; Abd-Elsalam, S.; Yousef, M.; Soliman, S.; Ali, L.A.; Elkhalawany, W.; Amer, I.; Harras, H.; Hagras, M.M.; Elhendawy, M. Helicobacter pylori may be an initiating factor in newly diagnosed ulcerative colitis patients: A pilot study. World J. Clin. Cases, 2018, 6(13), 641-649.
[http://dx.doi.org/10.12998/wjcc.v6.i13.641] [PMID: 30430119]
[19]
Della Monica, P.; Lavagna, A.; Masoero, G.; Lombardo, L.; Crocellá, L.; Pera, A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment. Pharmacol. Ther., 2002, 16(7), 1269-1275.
[http://dx.doi.org/10.1046/j.1365-2036.2002.01244.x] [PMID: 12144576]
[20]
Shehata, MA; Talaat, R; Soliman, S Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter, 2017, 22(5) .
[21]
Abd-Elsalam, S.; Kobtan, A.; El-Kalla, F.; Elkhalawany, W.; Nawasany, S.E.; Saif, S.A.; Yousef, M.; Ali, L.A.; Soliman, S.; Mansour, L.; Habba, E.; Soliman, H.; Rizk, F.; Shehata, M.A. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore), 2016, 95(24), e3879.
[http://dx.doi.org/10.1097/MD.0000000000003879] [PMID: 27310977]
[22]
Ismail, W.A.; Mostafa, E.F. Comparison between conventional triple therapy and sequential therapy on tolerance of treatment and eradication of Helicobacter pylori infection in Egyptian patients. Egypt. J. Intern. Med., 2018, 2018(30), 90-95.
[http://dx.doi.org/10.4103/ejim.ejim_6_18]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy